8/12/2010

The FDA said it would give priority review to Xifaxan, from Salix Pharmaceuticals, as a treatment for irritable bowel syndrome. The drug already is approved for traveler's diarrhea and hepatic encephalopathy, and Phase III clinical trials showed it lessens the abdominal pain and bloating of IBS.

Related Summaries